KUKJE PHARMA Co., Ltd. (002720) Stock Price & Analysis

002720 Stock Chart & Stats

₩3,345.00-₩55.00(-1.62%)

At close: Oct 30 3:30 PM GMT+9

Day’s Range: KRW 3,260.00 - KRW 3,405.00
52-Week Range: KRW 2,810.00 - KRW 5,470.00
Previous Close: KRW 3,400.00
Volume: N/A
Average Volume (3M): 3.90M
Market Cap: KRW 68.11B
Enterprise Value: KRW 85.92B
Total Cash (Recent Filing): KRW 15.72B
Total Debt (Recent Filing): KRW 31.39B
Price to Earnings (P/E): 13.9
Beta: -0.08
Next Earnings: Nov 12, 2026 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Mar 12, 2026
Dividend Yield: 0.90%

Bulls Say, Bears Say

Bulls Say

Strong TTM Revenue Rebound

The sharp TTM revenue rebound indicates stronger recent commercial performance and expanding sales activity. Combined with a solid gross margin, this provides a foundation for maintaining product investment and supporting future earnings, although sustained execution will determine how durable the improvement becomes.

Improving Balance Sheet

Lower debt relative to equity improves financial flexibility and reduces the burden that leverage can place on operating cash flow. The stronger balance-sheet position should give KUKJE PHARMA more capacity to manage business fluctuations and fund ongoing pharmaceutical activities over the next several quarters.

Positive TTM Cash Generation

Positive operating and free cash flow show that the company is generating cash from its business rather than relying entirely on external financing. This supports routine investment and financial resilience, even though the quality and consistency of cash conversion remain important constraints.

Bears Say

Thin And Compressed Profit Margins

Thin and declining operating and net margins leave limited room to absorb cost increases or weaker demand without affecting earnings. The compression also suggests that recent revenue growth has not translated proportionately into profitability, which may limit durable earnings expansion.

Historical Earnings Volatility

A prior loss and periods of negative returns indicate that profitability can be sensitive to operating swings. This history reduces confidence that the recent rebound will translate into consistently strong earnings, making future performance more dependent on sustaining favorable business conditions.

Weak Cash-Flow Conversion

Low conversion of reported earnings into free cash flow means accounting profitability is not fully reaching available cash resources. Sharply negative TTM free-cash-flow growth further points to greater reinvestment or working-capital demands, potentially increasing volatility in funding and capital allocation.

002720 FAQ

What was KUKJE PHARMA Co., Ltd.’s price range in the past 12 months?

KUKJE PHARMA Co., Ltd. lowest stock price was ₩2810.00 and its highest was ₩5470.00 in the past 12 months.

What is KUKJE PHARMA Co., Ltd.’s market cap?

KUKJE PHARMA Co., Ltd.’s market cap is ₩68.11B.

When is KUKJE PHARMA Co., Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were KUKJE PHARMA Co., Ltd.’s earnings last quarter?

KUKJE PHARMA Co., Ltd. released its earnings results on Aug 14, 2026. The company reported ₩78.932 earnings per share for the quarter.

Is KUKJE PHARMA Co., Ltd. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does KUKJE PHARMA Co., Ltd. pay dividends?

KUKJE PHARMA Co., Ltd. pays a ― dividend of ₩30 which represents an annual dividend yield of 0.9%. See more information on KUKJE PHARMA Co., Ltd. dividends here

What is KUKJE PHARMA Co., Ltd.’s EPS estimate?

KUKJE PHARMA Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does KUKJE PHARMA Co., Ltd. have?

KUKJE PHARMA Co., Ltd. has 21,159,832 shares outstanding.

What happened to KUKJE PHARMA Co., Ltd.’s price movement after its last earnings report?

KUKJE PHARMA Co., Ltd. reported an EPS of ₩78.932 in its last earnings report. Following the earnings report the stock price went down -0.74%.

Which hedge fund is a major shareholder of KUKJE PHARMA Co., Ltd.?

Currently, no hedge funds are holding shares in KR:002720

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description